Chronic Obstructive Pulmonary Disease (COPD) Pipeline Comprises 65 Drug Candidates in Different Stages of Development: P&S Market Research

NEW YORK, Aug. 24, 2017 -- Chronic obstructive pulmonary disease (COPD) is a broad term used for progression of various diseases affecting the lungs such as, chronic bronchitis, some forms of bronchiectasis, emphysema and refractory (non-reversible) asthma. Breathlessness and coughing are few of the early symptoms that induce the hypothesis of having COPD, but some people also consider these symptoms as the signs of aging. In no time, these ailments come under severe progression and reveal the rising of other associated diseases. The primary diagnosis of COPD is spirometry, which is the most common form of pulmonary function test that includes measurement of volume and flow of inhaled and exhaled air in the lungs. Therefore, analyzing the breathing pattern may assess the complications involved with the lungs. COPD is a disease that develops over the years and the associated symptoms are wheezing, tightness in chest, increased breathlessness and frequent coughing.

Browse Report Summary on Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis

In COPD, the lungs cells lose their quality of elasticity, most of the air sacs are destroyed, and the walls of the airways become thick and inflamed and in some cases also become clogged by mucus. Chronic bronchitis and emphysema are the two-main conditions that progress throughout the period of progression of the disease, due to which air sacs lose their shape and become floppy. The destruction of walls of air sacs leads to the enlargement of these sacs, and they no longer remain in their normal shape, which further leads to reduction in the amount of gas exchange in the lungs. According to the data provided by National Institutes of Health (NIH), nearly 12 million adults in the U.S. are suffering from COPD, of which 120,000 people die every year. Therefore, various combination therapies and advanced technologies are driving the growth of chronic obstructive pulmonary disease pipeline. Also, drug manufacturing companies are using various promising targets for the treatment of the disease. Targeted therapy is more effective in achieving good results. The potential targets will possibly stop or slow the progression of the disease with better efficacy and lesser side effects.

Make Enquiry Before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=copd-therapeutics-pipeline-analysis

As of May 2017, the COPD therapeutics pipeline comprises approximately 65 drug candidates in different stages of development.

Some of the key players developing drugs for the treatment of COPD include Chiesi Farmaceutici S.p.A., AstraZeneca plc, GlaxoSmithKline plc and others.

More Reports by P&S Market Research

Fibromyalgia Therapeutics Pipeline Analysis, 2017

Fibromyalgia therapeutic pipeline is expected to experience a positive trend in the coming years. Prevalence of fibromyalgia is increasing due to very large number of patients suffering from lifestyle disease, psychological stress, trauma, tension, headaches, anxiety and depression. Some of the significant factors driving the pipeline for fibromyalgia include rising prevalence of fibromyalgia and the increasing health awareness among the population, globally.

https://www.psmarketresearch.com/market-analysis/fibromyalgia-therapeutics-pipeline-analysis

Ankylosing Spondylitis Therapeutics Pipeline Analysis, 2017

Considerable growth in therapeutic pipeline of ankylosing spondylitis is attributed to the increase in prevalence of the disease among teens as well as young adult patients. Researchers have not been able to identify the actual cause of the disease. Novel anti-inflammatory agents and pain killers are being developed that are primarily responsible for the growth of therapeutics pipeline for ankylosing spondylitis.

https://www.psmarketresearch.com/market-analysis/ankylosing-spondylitis-therapeutics-pipeline-analysis

Cataract Therapeutics Pipeline Analysis, 2017

Considerable growth in therapeutic pipeline of cataract is expected in the future which could be attributed primarily to the increasing prevalence of cataract. According to researchers, smoking and diabetes are considered to be the major causes of cataract disease. Consumption of unhygienic crops and fruits, unhealthy lifestyle and rising level of pollutants in the environment are some of other important factors responsible for increasing incidence of cataract disease.

https://www.psmarketresearch.com/market-analysis/cataract-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook